Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Pharmaceuticals sales up 12% in the quarter driven by Entresto and Cosentyx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis

4Q Revenues: $12.4 billion (+8%)

4Q Earnings: $1.1 billion (-5%)

FY Revenues: $47.4 billion (+6%)  

FY Earnings: $11.7 billion (-7%)

Comments: Pharmaceuticals sales grew 12% to $6.2 billion in the quarter, driven by continued momentum of Entresto with sales of $518 million, up 63%, and Cosentyx with $965 million in sales, up 20%, and the launch uptake of Zolgensma with $186 million in sales. Oncology sales grew 7% driven by continued momentum on Kisqali with $155 million in sales, up 158%, and Kymriah with $96 million in sales, and the launch uptake of Piqray with $67 million in sales. Generic competition had a negative impact of 2 percentage points. Gilenya sales were $803 million, down 4%. Zolgensma sales were $186 million, continued a strong launch performance. Xolair sales were $303 million, up 13% in the quarter. Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew to $425 million, up 9%, driven by growth in Europe from Hyrimoz, Rixathon and Erelzi, partly offset by one-time sales reversals in biopharmaceutical contract manufacturing.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters